Imagion Biosystems Limited (ASX:IBX)

Market Cap	7.14M
Revenue (ttm)	1.06M
Net Income (ttm)	-2.20M
Shares Out	246.34M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,700,977
Average Volume	9,843,816
Open	0.0320
Previous Close	0.0330
Day's Range	0.0290 - 0.0370
52-Week Range	0.0110 - 0.0800
Beta	1.02
RSI	73.83
Earnings Date	Aug 28, 2025

About Imagion Biosystems

Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has collaboration with Siemens MRI to support the Phase 2 study of MagSense HER2 imaging agent...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IBX

Financial Performance

In 2024, Imagion Biosystems's revenue was 2.67 million, a decrease of -46.38% compared to the previous year's 4.97 million. Losses were -2.07 million, -83.43% less than in 2023.